Jules Bordet Institute
π§πͺBelgium
- Country
- π§πͺBelgium
- Ownership
- Private
- Established
- 1939-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.bordet.be
Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2013-07-31
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT01913067
- Locations
- π§πͺ
Institut Jules Bordet, Brussels, Belgium
A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer
- First Posted Date
- 2013-05-30
- Last Posted Date
- 2018-11-27
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 27
- Registration Number
- NCT01864798
- Locations
- π¦πΊ
Royal Melbourne Hospital, Victoria, Australia
π§πͺInstitute Jules Bordet, Brussels, Belgium
π§πͺHopital Erasme, Brussels, Belgium
Randomized Phase III of PRRT Versus Interferon
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT01860742
- Locations
- π§πͺ
UZ Leuven, Leuven, Belgium
π§πͺJules Bordet Institute, Brussels, Belgium
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01843725
- Locations
- π§πͺ
Institut Jules Bordet, Brussels, Belgium
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2022-11-10
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01842165
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01834469
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 19
- Registration Number
- NCT01709487
- Locations
- π§πͺ
Institut Jules Bordet, Brussels, Belgium
π§πͺHopital de la Citadelle, LiΓ¨ge, Belgium
Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2015-07-01
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 10
- Registration Number
- NCT01686880
- Locations
- π§πͺ
Institut Jules Bordet, Brussels, Belgium
π§πͺErasme Hosptial, Brussels, Belgium
Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-01-06
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 142
- Registration Number
- NCT01658956
- Locations
- π§πͺ
Institut Jules Bordet, Brussels, Belgium
Correlating the Tumoral Metabolic Progression Index to Patient's Outcome in Advanced Colorectal Cancer
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 53
- Registration Number
- NCT01591590
- Locations
- π§πͺ
Jules Bordet Institute, Brussels, Belgium
Β© Copyright 2024. All Rights Reserved by MedPath